Human proislet peptide - Boston Therapeutics

Drug Profile

Human proislet peptide - Boston Therapeutics

Alternative Names: BTI-410; HIP-2B; Pancreate; Proisletide acetate - CureDM

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CureDM
  • Developer Boston Therapeutics
  • Class Antihyperglycaemics; Peptides
  • Mechanism of Action Cell differentiation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 06 Apr 2018 Human proislet peptide is at phase I development stage for Type-1 diabetes mellitus and Type-2 diabetes mellitus in USA (SC) (Boston Therapeutics pipeline, April 2018)
  • 27 Mar 2018 Boston Therapeutics plans a pivotal phase II trial for Type 1 diabetes mellitus (in immunosuppressed kidney transplant patients) in USA
  • 27 Mar 2018 Boston Therapeutics plans a pivotal phase II trial for Type 2 diabetes mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top